A BREAKTHROUGH IN PDT TECHNOLOGY

Our DigiLum™ PDT light activation system incorporates novel optical device technology that presents a revolutionary new PDT light delivery & dosimetry method that is fast, precise, and easy to apply.  This breakthrough system is paired with Gleolan™ - a novel photosensitizer agent with a known safety profile and negligible side effects. Together this PDT platform enables broad clinical adoption of this proven therapy to expand its use to more cancer sites. Our lead indication is to apply PDT as an adjuvant therapy to work in combination with immune checkpoint blockade as a more effective and tolerable treatment for patients with late-stage lung cancer to unlock the potential for more patients to experience a full response to immunotherapy- a key challenge in lung cancer treatment today.

Our therapeutic solution is applied intraoperatively during video-assisted thoracoscopic surgery (VATS) and robotic-assisted laparoscopic surgery procedures. Extensions of the product are planned for use in endoscopic and robotic procedures for a new interventional oncology platform. Use of Gleolan™ allows potential theranostic “see and treat” applications for enhanced visualization and adjuvant therapy for local control during surgical procedures. A Phase I/II clinical study is planned to open in 2024 to evaluate the use of the platform to improve surgical visualization and apply adjunct therapy following tumor resection to address positive tumor margins in treating patients with advanced or recurrent colorectal cancer undergoing surgery.